ClinicalTrials.gg
CompletedNCT06379893Updated Jan 20, 2026Results posted

A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain

A Phase 4 interventional study of Voltaren Gel in Pain, sponsored by HALEON. Completed at 8 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by HALEON · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
196
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies in Pain with a site in Poland — 9 open to participants now, 9 under way, none of them phase 3. Pain · Poland.

Enrollment
47th of 89
196 · median 200
Started
2024
with 1 other
Phase 4
4 of 97
1 open now
Registered
86th of 97
by date

Among the 97 studies in Pain with a site in Poland, this one is the 47th largest by enrollment of the 89 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 4, and was the 86th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

9 of the 97 studies in Pain with a site in Poland are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Pain with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to investigate how topical diclofenac use can improve functional mobility and physical activity primarily, as well as other quality-of-life (QoL) parameters such as sleep, mood, and engagement in daily activities in participants with knee OA.

Read the detailed description

This prospective open-label, single-arm, multi-country (United States [US] and European Union [EU]) real-world evidence study will be conducted in a hybrid form and will focus on assessing the impact of Voltaren Gel on functional mobility and QoL in individuals with mild/nonserious OA of the knee. Participants will be required to be physically present at the study site for screening, end of baseline and end of study visits. The remaining treatment will be conducted in a remote manner (for example, at home) to observe the real-world usage of Voltaren Gel. This study will utilize a research-grade validated wearable device: Actigraph, to accurately measure objective changes in functional mobility. Sufficient participants will be screened to enroll approximately 195 participants to ensure that around 147 of these participants will successfully complete the entire study.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant is male or female who, at the time of screening, is between the ages of 40 and 85 years, inclusive.
  • A participant who is willing and able to comply with scheduled visits, on-label Voltaren Gel use plan, and other study procedures.
  • A participant willing to wear Actigraph continuously 24/7 for the study period.
  • A participant in good general and mental health.
  • A participant with diagnosed knee mild/non-serious osteoarthritis, proven via radiological evidence collected within the last 3 years.
  • A participant with self-reported knee pain, with a score of greater than or equal to (>=) 40 millimeters (mm) less than or equal to (\<=)70mm on the pain intensity visual analogue scale at the time of Informed Consent Form (ICF) signature.
  • A participant willing to use Voltaren Gel for up to 3 weeks.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 1 month prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant with confirmed rheumatologic disease
  • A participant who has experienced trauma to the knee within the last 2 months that resulted in pain and/or swelling.
  • A participant that has been administered local or other Non-steroidal anti-inflammatory drugs (NSAIDs) injections to the knee within the last 3 months.
  • A participant with recent history of major knee injury or surgery.
  • A participant with knee skin area pathological condition which prevents application of product to the skins. Conditions such as: open skin wounds, infections, inflammations, or exfoliative dermatitis conditions.
  • A participant with conditions not limited to the following: Gastrointestinal diseases, asthma, hypertension, myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function, or liver disease as judged by investigator or Site Staff.
  • A participant diagnosed with other relevant medical conditions (example, psychiatric, neurological).
  • A participant who takes medication relating to above conditions, such as tricyclic antidepressants or anticonvulsants.
  • A participant with an active infection.
  • A participant who is pregnant, lactating, or plan to be pregnant or lactating during the study.
  • A participant with use of aspirin, Oral NSAIDs, topical treatment with any NSAIDs, warfarin, Angiotensin-converting enzyme (ACE) inhibitors, cyclosporine, diuretics, lithium or methotrexate, corticosteroids, or other anticoagulant therapy within 30 days of study.
  • A participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients, including hypersensitivity to NSAIDs and aspirin triad.
  • A participant with any other acute or chronic illness that could compromise the integrity of study data or place the participant at risk by participating in the study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Voltaren Gel

    Participants will use Voltaren Gel topically, applied daily as per label and leaflet instructions for up to 21 days. Participants will be instructed to wear Actigraph device on the wrist as per label, leaflet or site-specific instructions post training throughout the day for up to 21 days.

    Drug: Voltaren Gel

Interventions

  • Diclofenac sodium gel in 3 different concentrations as- Diclofenac sodium 1%, 1.16% and 2.32% whichever was available in the given region.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1

    The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A mixed model with repeated measures (MMRM) was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 1. Baseline value was calculated as the sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement. Modified Intent-To-Treat (mITT) population included all participants who met the inclusion/exclusion criteria, who used study product at least once and had data from at least one post Baseline quality of life (QoL) questionnaire to support at least one of the secondary endpoint assessments.

    Time frame: Baseline and Week 1

  2. Change From Baseline in the Average Minutes of MVPA at Week 2

    The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 2. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

    Time frame: Baseline and Week 2

  3. Change From Baseline in the Average Minutes of MVPA at Week 3

    The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 3. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

    Time frame: Baseline and Week 3

Secondary outcomes

  1. Change From Baseline in Daily Average Number of Steps Taken at Weeks 1, 2 and 3

    Daily average number of steps taken were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. MMRM was used to analyse the change from Baseline in daily average number of steps taken. Change from Baseline was calculated by subtracting the average number of steps taken at Baseline from the average number of steps taken at each indicated post-Baseline timepoint. Baseline value was calculated as the sum of steps taken over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  2. Change From Baseline in Ratio of Sedentary/Non-sedentary Time at Weeks 1, 2 and 3

    Sedentary/non-sedentary time was measured using a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. Ratio of sedentary/non-sedentary time was calculated as = Total number of minutes defined as sedentary behaviour divided by Total number of non-sedentary behaviour minutes where number of non-sedentary behaviour minutes in the day was derived as the sum of light activity and MVPA. Change from Baseline was calculated by subtracting the Baseline ratio of sedentary/non-sedentary time from the ratio at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  3. Change From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Cadence at Weeks 1, 2 and 3

    Gait was assessed through speed and step irregularity measured via cadence using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated as by subtracting the average cadence at Baseline from the cadence at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  4. Change From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Gait Speed at Weeks 1, 2 and 3

    Gait was assessed through speed and step irregularity measured via gait speed using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated by subtracting the average gait speed at Baseline from the Average gait speed at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  5. Change From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 30 Minutes Post-wake at Weeks 1, 2 and 3

    Indices of morning stiffness were assessed through levels of mobility 30 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 30 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 30 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 30 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  6. Change From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 60 Minutes Post-wake at Weeks 1, 2 and 3

    Indices of morning stiffness were assessed through levels of mobility 60 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 60 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 60 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 60 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  7. Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Physical Function Subscale Score at Week 1, 2 and 3

    Participants completed the WOMAC questionnaire daily using eDiary. The WOMAC questionnaire consisted of 24 questions categorised in 3 subscales - Pain, Stiffness, Physical function. The physical function subscale consisted of 17 questions related to level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions. Change from Baseline was calculated by subtracting the normalized WOMAC subscale score at Baseline from the normalized WOMAC subscale score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  8. MVPA on Each Day of the Study

    The average minutes of MVPA on each day were measured through a connected activity tracker (Actigraph device) worn by the participants to assess the functional mobility. Baseline was calculated as the average of MVPA values collected during the Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0.

    Time frame: Baseline up to Day 21

  9. WOMAC Physical Function Subscale Score at Weeks 1, 2 and 3

    Physical function subscale score of the WOMAC questionnaire was used to study participant's perceived ability to exercise more regularly. It consisted of 17 questions related to the level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions.

    Time frame: Week 1, Week 2 and Week 3

  10. Change From Baseline in Self-reported Pain Intensity Assessed Through Numeric Rating Scale (NRS) at Weeks 1, 2 and 3

    Participants rated the pain intensity experienced by them daily within the eDiary, using NRS. NRS is an 11-point scale with scores ranging from 0 to 10 where score 0 = no pain, 1 = slight pain, 2-3 = mild pain, 4-6 = moderate pain, 7 = severe pain, 8 to 9 = extreme pain, 10=pain as bad as it could be. Higher scores indicated greater pain intensity. Change from Baseline was calculated by subtracting the Baseline NRS score from the NRS score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  11. Change From Baseline in the WOMAC Total Score at Weeks 1, 2 and 3

    Participants completed the WOMAC questionnaire daily. The WOMAC questionnaire consisted of 24 questions each scored on a 5-point scale: 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The WOMAC questionnaire was categorized in 3 subscales - Pain (5 questions, score ranges 0-20), Stiffness (2 questions, score ranges 0-8), Physical function (17 questions, score ranges 0-68). Each subscale score was normalized on a 0 to 100 scale calculated as: Pain subscale score= (sum of raw score items in dimension)\*5; Stiffness subscale score= (sum of raw score items in dimension)\*12.5; Physical function subscale score= (sum of raw score items in dimension)\*1.47. WOMAC Total score = sum of the 3 normalized WOMAC subscale scores. Thus, WOMAC total score ranges from 0 to 300 with 0 being the best and 300 being the worst. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  12. Change From Baseline in the WOMAC Pain Subscale Score at Weeks 1, 2 and 3

    The pain subscale of the WOMAC questionnaire consisted of 5 questions related to severity of pain experienced by the participant when walking, stair climbing, at night, at rest, weightbearing, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale ranging from 0 to 4 daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total pain subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*5. Higher scores indicated more pain. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC pain subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  13. Change From Baseline in the WOMAC Stiffness Subscale Score at Weeks 1, 2 and 3

    The stiffness subscale of the WOMAC questionnaire consisted of 2 questions related to severity of stiffness experienced by the participant at morning and during the day, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale with scores ranging from 0 to 4 daily using eDiary, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total stiffness subscale score for was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*12.5. Higher scores indicated more stiffness. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC stiffness subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 1, Week 2 and Week 3

  14. Change From Baseline in Sleep/Alertness Assessed Using Karolinska Sleepiness Scale (KSS) at Days 7, 14 and 21

    KSS measured the subjective level of sleepiness/alertness during the day. Participants rated how sleepy or alert they were feeling using KSS with scores ranging from 1 to 9 where 1 = extremely alert, 2 = very alert, 3 = alert, 4 = fairly alert, 5 = neither alert nor sleepy, 6 = some signs of sleepiness, 7 = sleepy, but no efforts to keep alert, 8 = sleepy, some efforts to keep alert, 9 = very sleepy, great effort to keep alert, fighting sleep. Higher scores indicated greater sleepiness. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Day 7, Day 14, and Day 21

  15. Change From Baseline in Health-related QoL Assessed Using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire at Days 7, 14, and 21

    Health-related QoL of participants was assessed using the EQ-5D-5L questionnaire. It consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) with 5 response levels for each dimension where Level 1 = no problems, Level 2 = slight problems, Level 3 = moderate problems, Level 4 = severe problems, Level 5 = unable to perform activities/extreme problems. Participants were asked to indicate their health by ticking the box next to the most appropriate response level for each dimension. The response levels were used to derive a health index score based on the Crosswalk Value Set for the United States ranging from less than 0 (worst imaginable health) to 1 (best imaginable health) where higher scores indicated better health. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated timepoint. Baseline was defined as Day 0. A positive change from Baseline indicated improvement.

    Time frame: Baseline, Days 7, 14 and 21

07

Results

Posted Jan 20, 2026

Participant flow

This study was conducted at 2 centers in the United States (US) and 6 centers in the European Union (EU) (Poland).

Participant flow — Overall Study
MilestoneVoltaren Gel
Started196
Completed194
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Sponsors' decision1

Outcome measures

PrimaryChange From Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1

The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A mixed model with repeated measures (MMRM) was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 1. Baseline value was calculated as the sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement. Modified Intent-To-Treat (mITT) population included all participants who met the inclusion/exclusion criteria, who used study product at least once and had data from at least one post Baseline quality of life (QoL) questionnaire to support at least one of the secondary endpoint assessments.

Time frame:
Baseline and Week 1
Reported as:
Mean · minutes
Change From Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1
minutesVoltaren Gel
Baseline249.2 ± 92.99
Change from Baseline at Week 114.2 ± 53.54
Statistical analysis
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: 15.6 · 95% CI 8.3 to 22.8
PrimaryChange From Baseline in the Average Minutes of MVPA at Week 2

The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 2. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

Time frame:
Baseline and Week 2
Reported as:
Mean · minutes
Change From Baseline in the Average Minutes of MVPA at Week 2
minutesVoltaren Gel
Baseline249.2 ± 92.99
Change from Baseline at Week 210.7 ± 60.93
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.001 · Least square means: 13 · 95% CI 5.2 to 20.9
PrimaryChange From Baseline in the Average Minutes of MVPA at Week 3

The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 3. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

Time frame:
Baseline and Week 3
Reported as:
Mean · minutes
Change From Baseline in the Average Minutes of MVPA at Week 3
minutesVoltaren Gel
Baseline249.2 ± 92.99
Change from Baseline at Week 3-0.8 ± 71.08
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.653 · Least square means: 2.1 · 95% CI -7.1 to 11.3
SecondaryChange From Baseline in Daily Average Number of Steps Taken at Weeks 1, 2 and 3

Daily average number of steps taken were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. MMRM was used to analyse the change from Baseline in daily average number of steps taken. Change from Baseline was calculated by subtracting the average number of steps taken at Baseline from the average number of steps taken at each indicated post-Baseline timepoint. Baseline value was calculated as the sum of steps taken over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · steps
Change From Baseline in Daily Average Number of Steps Taken at Weeks 1, 2 and 3
stepsVoltaren Gel
Baseline13826.5 ± 5076.05
Change from Baseline at Week 1602.3 ± 2930.69
Change from Baseline at Week 2323.1 ± 3515.66
Change from Baseline at Week 3-57.1 ± 3826.57
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.001 · Least square means: 707 · 95% CI 278.9 to 1135
  • Voltaren Gel · MMRM · p = 0.040 · Least square means: 487.3 · 95% CI 22 to 952.6
  • Voltaren Gel · MMRM · p = 0.603 · Least square means: 130.8 · 95% CI -365.6 to 627.2
SecondaryChange From Baseline in Ratio of Sedentary/Non-sedentary Time at Weeks 1, 2 and 3

Sedentary/non-sedentary time was measured using a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. Ratio of sedentary/non-sedentary time was calculated as = Total number of minutes defined as sedentary behaviour divided by Total number of non-sedentary behaviour minutes where number of non-sedentary behaviour minutes in the day was derived as the sum of light activity and MVPA. Change from Baseline was calculated by subtracting the Baseline ratio of sedentary/non-sedentary time from the ratio at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · ratio
Change From Baseline in Ratio of Sedentary/Non-sedentary Time at Weeks 1, 2 and 3
ratioVoltaren Gel
Baseline1.984 ± 1.1595
Change from Baseline at Week 1-0.028 ± 0.5376
Change from Baseline at Week 20.003 ± 0.5571
Change from Baseline at Week 30.089 ± 0.6121
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.473 · Least square means: -0.028 · 95% CI -0.105 to 0.049
  • Voltaren Gel · MMRM · p = 0.835 · Least square means: 0.009 · 95% CI -0.074 to 0.091
  • Voltaren Gel · MMRM · p = 0.014 · Least square means: 0.110 · 95% CI 0.023 to 0.198
SecondaryChange From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Cadence at Weeks 1, 2 and 3

Gait was assessed through speed and step irregularity measured via cadence using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated as by subtracting the average cadence at Baseline from the cadence at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · steps per minute
Change From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Cadence at Weeks 1, 2 and 3
steps per minuteVoltaren Gel
Baseline109.207 ± 6.8045
Change from Baseline at Week 1-0.149 ± 6.3135
Change from Baseline at Week 2-1.126 ± 11.7981
Change from Baseline at Week 3-1.751 ± 14.7336
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.261 · Least square means: 0.261 · 95% CI -0.196 to 0.717
  • Voltaren Gel · MMRM · p = 0.263 · Least square means: 0.249 · 95% CI -0.188 to 0.685
  • Voltaren Gel · MMRM · p = 0.854 · Least square means: 0.053 · 95% CI -0.512 to 0.617
SecondaryChange From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Gait Speed at Weeks 1, 2 and 3

Gait was assessed through speed and step irregularity measured via gait speed using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated by subtracting the average gait speed at Baseline from the Average gait speed at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · meters per second
Change From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Gait Speed at Weeks 1, 2 and 3
meters per secondVoltaren Gel
Baseline1.010 ± 0.1385
Change from Baseline at Week 1-0.007 ± 0.0809
Change from Baseline at Week 2-0.016 ± 0.1069
Change from Baseline at Week 3-0.016 ± 0.1401
SecondaryChange From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 30 Minutes Post-wake at Weeks 1, 2 and 3

Indices of morning stiffness were assessed through levels of mobility 30 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 30 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 30 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 30 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · vector magnitude counts
Change From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 30 Minutes Post-wake at Weeks 1, 2 and 3
vector magnitude countsVoltaren Gel
Baseline75593.364 ± 44958.5420
Change from Baseline at Week 11969.758 ± 28283.0182
Change from Baseline at Week 22332.422 ± 28420.8109
Change from Baseline at Week 3-1893.342 ± 34458.1863
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.221 · Least square means: 2415.2 · 95% CI -1466.3 to 6296.8
  • Voltaren Gel · MMRM · p = 0.127 · Least square means: 3041.7 · 95% CI -868.5 to 6951.9
  • Voltaren Gel · MMRM · p = 0.314 · Least square means: -2428.7 · 95% CI -7177.5 to 2320.1
SecondaryChange From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 60 Minutes Post-wake at Weeks 1, 2 and 3

Indices of morning stiffness were assessed through levels of mobility 60 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 60 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 60 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 60 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · vector magnitude counts
Change From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 60 Minutes Post-wake at Weeks 1, 2 and 3
vector magnitude countsVoltaren Gel
Baseline149034.401 ± 86661.4977
Change from Baseline at Week 12891.276 ± 45249.4973
Change from Baseline at Week 22438.403 ± 48859.7477
Change from Baseline at Week 3-6734.944 ± 54957.9211
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.289 · Least square means: 3409.9 · 95% CI -2911.4 to 9731.2
  • Voltaren Gel · MMRM · p = 0.303 · Least square means: 3552.3 · 95% CI -3240.4 to 10345.1
  • Voltaren Gel · MMRM · p = 0.046 · Least square means: -7820.7 · 95% CI -15512.8 to -128.5
SecondaryChange From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Physical Function Subscale Score at Week 1, 2 and 3

Participants completed the WOMAC questionnaire daily using eDiary. The WOMAC questionnaire consisted of 24 questions categorised in 3 subscales - Pain, Stiffness, Physical function. The physical function subscale consisted of 17 questions related to level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions. Change from Baseline was calculated by subtracting the normalized WOMAC subscale score at Baseline from the normalized WOMAC subscale score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · score on a scale
Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Physical Function Subscale Score at Week 1, 2 and 3
score on a scaleVoltaren Gel
Baseline48.702 ± 12.9284
Change from Baseline at Week 1-8.677 ± 12.6188
Change from Baseline at Week 2-11.926 ± 14.0764
Change from Baseline at Week 3-15.644 ± 16.9641
Statistical analysis
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -8.392 · 95% CI -10.196 to -6.588
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -11.882 · 95% CI -13.946 to -9.818
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -15.929 · 95% CI -18.320 to -13.537
SecondaryMVPA on Each Day of the Study

The average minutes of MVPA on each day were measured through a connected activity tracker (Actigraph device) worn by the participants to assess the functional mobility. Baseline was calculated as the average of MVPA values collected during the Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0.

Time frame:
Baseline up to Day 21
Reported as:
Mean · minutes
MVPA on Each Day of the Study
minutesVoltaren Gel
Baseline249.2 ± 92.99
Day 1274.1 ± 119.79
Day 2268.4 ± 124.96
Day 3259.3 ± 124.79
Day 4270.8 ± 126.09
Day 5255.8 ± 115.05
Day 6255.1 ± 119.03
Day 7260.4 ± 112.45
Day 8264.2 ± 122.21
Day 9258.0 ± 126.33
Day 10266.5 ± 128.05
Day 11262.9 ± 124.18
Day 12252.0 ± 122.99
Day 13261.3 ± 122.89
Day 14254.3 ± 114.00
Day 15254.6 ± 124.49
Day 16250.3 ± 114.15
Day 17251.1 ± 122.16
Day 18253.8 ± 124.67
Day 19239.1 ± 118.63
Day 20244.0 ± 120.81
Day 21107.8 ± 85.88
SecondaryWOMAC Physical Function Subscale Score at Weeks 1, 2 and 3

Physical function subscale score of the WOMAC questionnaire was used to study participant's perceived ability to exercise more regularly. It consisted of 17 questions related to the level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions.

Time frame:
Week 1, Week 2 and Week 3
Reported as:
Mean · score on a scale
WOMAC Physical Function Subscale Score at Weeks 1, 2 and 3
score on a scaleVoltaren Gel
Week 140.375 ± 14.7527
Week 237.072 ± 15.9130
Week 332.781 ± 17.2916
SecondaryChange From Baseline in Self-reported Pain Intensity Assessed Through Numeric Rating Scale (NRS) at Weeks 1, 2 and 3

Participants rated the pain intensity experienced by them daily within the eDiary, using NRS. NRS is an 11-point scale with scores ranging from 0 to 10 where score 0 = no pain, 1 = slight pain, 2-3 = mild pain, 4-6 = moderate pain, 7 = severe pain, 8 to 9 = extreme pain, 10=pain as bad as it could be. Higher scores indicated greater pain intensity. Change from Baseline was calculated by subtracting the Baseline NRS score from the NRS score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · score on a scale
Change From Baseline in Self-reported Pain Intensity Assessed Through Numeric Rating Scale (NRS) at Weeks 1, 2 and 3
score on a scaleVoltaren Gel
Baseline5.7 ± 1.31
Change from Baseline at Week 1-1.5 ± 1.54
Change from Baseline at Week 2-1.9 ± 1.69
Change from Baseline at Week 3-2.6 ± 1.96
Statistical analysis
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -1.4 · 95% CI -1.7 to -1.2
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -2 · 95% CI -2.2 to -1.7
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -2.6 · 95% CI -2.9 to -2.3
SecondaryChange From Baseline in the WOMAC Total Score at Weeks 1, 2 and 3

Participants completed the WOMAC questionnaire daily. The WOMAC questionnaire consisted of 24 questions each scored on a 5-point scale: 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The WOMAC questionnaire was categorized in 3 subscales - Pain (5 questions, score ranges 0-20), Stiffness (2 questions, score ranges 0-8), Physical function (17 questions, score ranges 0-68). Each subscale score was normalized on a 0 to 100 scale calculated as: Pain subscale score= (sum of raw score items in dimension)\*5; Stiffness subscale score= (sum of raw score items in dimension)\*12.5; Physical function subscale score= (sum of raw score items in dimension)\*1.47. WOMAC Total score = sum of the 3 normalized WOMAC subscale scores. Thus, WOMAC total score ranges from 0 to 300 with 0 being the best and 300 being the worst. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · score on a scale
Change From Baseline in the WOMAC Total Score at Weeks 1, 2 and 3
score on a scaleVoltaren Gel
Baseline147.040 ± 38.1349
Change from Baseline at Week 1-27.359 ± 38.7623
Change from Baseline at Week 2-36.062 ± 42.4964
Change from Baseline at Week 3-47.852 ± 49.4526
Statistical analysis
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -26.529 · 95% CI -31.929 to -21.129
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -36.179 · 95% CI -42.090 to -30.269
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -48.834 · 95% CI -55.692 to -41.976
SecondaryChange From Baseline in the WOMAC Pain Subscale Score at Weeks 1, 2 and 3

The pain subscale of the WOMAC questionnaire consisted of 5 questions related to severity of pain experienced by the participant when walking, stair climbing, at night, at rest, weightbearing, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale ranging from 0 to 4 daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total pain subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*5. Higher scores indicated more pain. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC pain subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · score on a scale
Change From Baseline in the WOMAC Pain Subscale Score at Weeks 1, 2 and 3
score on a scaleVoltaren Gel
Baseline48.196 ± 13.2952
Change from Baseline at Week 1-9.458 ± 13.7044
Change from Baseline at Week 2-12.422 ± 14.5893
Change from Baseline at Week 3-16.383 ± 16.6274
Statistical analysis
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -9.213 · 95% CI -11.011 to -7.415
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -12.570 · 95% CI -14.519 to -10.621
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -16.408 · 95% CI -18.669 to -14.146
SecondaryChange From Baseline in the WOMAC Stiffness Subscale Score at Weeks 1, 2 and 3

The stiffness subscale of the WOMAC questionnaire consisted of 2 questions related to severity of stiffness experienced by the participant at morning and during the day, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale with scores ranging from 0 to 4 daily using eDiary, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total stiffness subscale score for was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*12.5. Higher scores indicated more stiffness. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC stiffness subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 1, Week 2 and Week 3
Reported as:
Mean · score on a scale
Change From Baseline in the WOMAC Stiffness Subscale Score at Weeks 1, 2 and 3
score on a scaleVoltaren Gel
Baseline50.142 ± 16.7965
Change from Baseline at Week 1-9.242 ± 18.6173
Change from Baseline at Week 2-11.719 ± 19.2063
Change from Baseline at Week 3-15.680 ± 20.6853
Statistical analysis
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -8.912 · 95% CI -11.401 to -6.423
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -11.699 · 95% CI -14.177 to -9.221
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -16.166 · 95% CI -18.858 to -13.473
SecondaryChange From Baseline in Sleep/Alertness Assessed Using Karolinska Sleepiness Scale (KSS) at Days 7, 14 and 21

KSS measured the subjective level of sleepiness/alertness during the day. Participants rated how sleepy or alert they were feeling using KSS with scores ranging from 1 to 9 where 1 = extremely alert, 2 = very alert, 3 = alert, 4 = fairly alert, 5 = neither alert nor sleepy, 6 = some signs of sleepiness, 7 = sleepy, but no efforts to keep alert, 8 = sleepy, some efforts to keep alert, 9 = very sleepy, great effort to keep alert, fighting sleep. Higher scores indicated greater sleepiness. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Day 7, Day 14, and Day 21
Reported as:
Mean · score on a scale
Change From Baseline in Sleep/Alertness Assessed Using Karolinska Sleepiness Scale (KSS) at Days 7, 14 and 21
score on a scaleVoltaren Gel
Baseline3.9 ± 1.60
Change from Baseline at Day 7-0.2 ± 1.56
Change from Baseline at Day 14-0.2 ± 1.70
Change from Baseline at Day 21-0.4 ± 1.66
Statistical analysis
  • Voltaren Gel · MMRM · p = 0.237 · Least square means: -0.1 · 95% CI -0.3 to 0.1
  • Voltaren Gel · MMRM · p = 0.071 · Least square means: -0.2 · 95% CI -0.4 to 0.0
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: -0.4 · 95% CI -0.6 to -0.2
SecondaryChange From Baseline in Health-related QoL Assessed Using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire at Days 7, 14, and 21

Health-related QoL of participants was assessed using the EQ-5D-5L questionnaire. It consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) with 5 response levels for each dimension where Level 1 = no problems, Level 2 = slight problems, Level 3 = moderate problems, Level 4 = severe problems, Level 5 = unable to perform activities/extreme problems. Participants were asked to indicate their health by ticking the box next to the most appropriate response level for each dimension. The response levels were used to derive a health index score based on the Crosswalk Value Set for the United States ranging from less than 0 (worst imaginable health) to 1 (best imaginable health) where higher scores indicated better health. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated timepoint. Baseline was defined as Day 0. A positive change from Baseline indicated improvement.

Time frame:
Baseline, Days 7, 14 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Health-related QoL Assessed Using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire at Days 7, 14, and 21
score on a scaleVoltaren Gel
Baseline0.67 ± 0.124
Change from Baseline at Day 70.04 ± 0.098
Change from Baseline at Day 140.05 ± 0.097
Change from Baseline at Day 210.07 ± 0.111
Statistical analysis
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: 0.04 · 95% CI 0.02 to 0.05
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: 0.05 · 95% CI 0.04 to 0.07
  • Voltaren Gel · MMRM · p = <0.001 · Least square means: 0.07 · 95% CI 0.05 to 0.09

Adverse events

Collected over From signing of informed consent form up to end of study (up to approximately 28 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voltaren Gel0/196 (0%)0/196 (0%)17/196 (8.7%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventVoltaren Gel
ArthralgiaMusculoskeletal and connective tissue disorders6/196
HeadacheNervous system disorders3/196
Muscle spasmsMusculoskeletal and connective tissue disorders1/196
MyalgiaMusculoskeletal and connective tissue disorders1/196
Ear infectionInfections and infestations1/196
SinusitisInfections and infestations1/196
Viral infectionInfections and infestations1/196
Viral upper respiratory tract infectionInfections and infestations1/196
ErythemaSkin and subcutaneous tissue disorders1/196
RashSkin and subcutaneous tissue disorders1/196

Baseline characteristics

The enrolled population included all participants who met the inclusion/exclusion criteria as recorded on the 'Participant Eligibility: Inclusion/Exclusion Criteria' electronic case report form (eCRF) page.

Age, Continuous
Age, Continuous(years)Voltaren Gel
Mean61.8 ± 9.33
Sex: Female, Male
Sex: Female, Male(Participants)Voltaren Gel
Female118
Male78
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Voltaren Gel
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White188
More than one race1
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Voltaren Gel
Hispanic or Latino19
Not Hispanic or Latino20
Missing157
08

Study locations

8 sites
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Quality Research Inc
    San Antonio, Texas 78209, United States
  • Vitamed Gałaj I Cichomski sp.j.
    Bydgoszcz, 85-079, Poland
  • Centrum Medyczne Lukamed.
    Chojnice, 89-600, Poland
  • Silmedic sp. z o.o.
    Katowice, 40-282, Poland
  • Santa Sp. z o.o. Santa Familia PTG Lodz
    Lodz, 90-302, Poland
  • Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp z .o.o
    Malbork, 82-200, Poland
  • Specjalistyczny Osrodek Lecziczo Badawczy (SOLB) Zbgniew Żęgota
    Ostróda, 14-100, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2024, 6 months.

Results were first posted in Jan 2026, 1 year 2 months after primary completion.

Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 23, 2024
StartActual
Apr 25, 2024
Primary completionActual
Oct 29, 2024
CompletionActual
Oct 29, 2024
Results first posted
Jan 20, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06379893
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Apr 25, 2024
Primary completion
Oct 29, 2024
Completion
Oct 29, 2024
Results posted
Jan 20, 2026
Last update
Jan 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion